Hsu J, Patel SN, Wolfe JD, et al. - In this randomized clinical trial, researchers contrasted the short-term effect of topical dorzolamide-timolol vs placebo in eyes with neovascular age-related macular degeneration that have persistent exudation following intravitreal anti-vascular endothelial growth factor (VEGF) injections. Participants in the study were 50 patients [mean (SD) age was 78.4 (7) years]. The authors discovered that patients randomized to use topical dorzolamide-timolol had no better vision vs placebo but had a greater reduction in central subfield thickness and maximum pigment epithelial detachment height from baseline to nearly 3 months. Such results indicate adjuvant dorzolamide-timolol decreases macular edema in patients with persistent exudation following frequent anti-VEGF injections, although this short-term trial did not detect any differences in visual acuity.